| Name | Title | Contact Details |
|---|---|---|
Daryl Gaugler |
Chief Operating Officer | Profile |
Corcoran Leary |
Associate Director, Information Security | Profile |
Scott Ring |
Director - Information Security | Profile |
Patricia McLeish |
Executive Director, Learning and Development | Profile |
We re committed to breakthrough firsts in womens sexual health. Novel ideas fuel our entrepreneurial passion. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we re trying to collectively accomplish.
ViTel Net is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
5strong healthcare is a Short Hills, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Schedule your appointment with a local hearing healthcare professional. See available times and providers, book online with EarQ, and start hearing better!
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.